Vaxart Inc (VXRT)

Currency in USD
0.5435
-0.0165(-2.95%)
Closed·
VXRT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.54310.5695
52 wk Range
0.30500.8449
Key Statistics
Prev. Close
0.56
Open
0.56
Day's Range
0.5431-0.5695
52 wk Range
0.305-0.8449
Volume
137.76K
Average Volume (3m)
335.92K
1-Year Change
48.4973%
Book Value / Share
0.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VXRT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.3333
Upside
+513.31%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Vaxart Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.3333
(+513.31% Upside)

Vaxart Inc Earnings Call Summary for Q2/2026

  • Vaxart missed Q2 2026 estimates with revenue of $27.2M (down 46% vs. forecast) and a 6-cent loss per share versus 3-cent expected loss.
  • Revenue fell 31.5% YoY due to lower BARDA contract revenue; R&D spending dropped 32.2%, narrowing net loss to $13.5M from $15M prior year.
  • Company holds $64M cash with runway into Q2 2027; BARDA released additional $29M for expanded COVID-19 trial analysis and completion.
  • Main COVID-19 trial (5,000 participants) fully enrolled; top-line efficacy and safety data expected in first half of 2027 per management guidance.
  • Shares fell 3.4% to $0.55; company pursuing non-dilutive funding including government contracts, partnerships, and $25M Lincoln Park facility.
Last Updated: 07/08/2026, 22:28
Read Full Transcript

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.06 / -0.03
Revenue / Forecast
27.19M / 50.5M
EPS Revisions
Last 90 days

VXRT Income Statement

Compare VXRT to Peers and Sector

Metrics to compare
VXRT
Peers
Sector
Relationship
P/E Ratio
3.4x−1.6x−0.4x
PEG Ratio
0.02−0.050.00
Price/Book
1.6x1.5x2.6x
Price / LTM Sales
0.5x129.6x3.1x
Upside (Analyst Target)
-429.6%48.3%
Fair Value Upside
Unlock17.2%6.2%Unlock

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
343.64K0.14%186.77K
Other Institutional Investors
-211.30K-0.09%-114.84K
Public Companies & Retail Investors
241.11M99.95%131.04M
Total
241.24M100.00%131.11M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vifag 2002 SICAV S.A.0.12%278,010151
Bg Fund Management Luxembourg S.A.0.03%64,91335

People Also Watch

4.8400
MNTS
-1.43%
59.900
LDOF
+1.01%
18.880
MRAM
+12.18%
12.860
INFQ
+5.58%
13.580
RDW
+2.88%

FAQ

What Is the Vaxart (VXRT) Stock Price Today?

The Vaxart stock price today is 0.5435 USD.

What Stock Exchange Does Vaxart Trade On?

Vaxart is listed and trades on the OTC Markets.

What Is the Stock Symbol for Vaxart?

The stock symbol for Vaxart is "VXRT."

What Is the Vaxart Market Cap?

As of today, Vaxart market cap is 131.9800M USD.

What Is Vaxart's Earnings Per Share (TTM)?

The Vaxart EPS (TTM) is 0.1620.

When Is the Next Vaxart Earnings Date?

Vaxart will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is VXRT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Vaxart Stock Split?

Vaxart has split 2 times.

How Many Employees Does Vaxart Have?

Vaxart has 65 employees.

What is the current trading status of Vaxart (VXRT)?

As of Aug 16, 2026, Vaxart (VXRT) is trading at a price of 0.5435 USD, with a previous close of 0.5600 USD. The stock has fluctuated within a day range of 0.5431 USD to 0.5695 USD, while its 52-week range spans from 0.3050 USD to 0.8449 USD.

What Is Vaxart (VXRT) Price Target According to Analysts?

The average 12-month price target for Vaxart is 3.3333 USD, with a high estimate of 4 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +513.31% Upside potential.

What Is the VXRT Premarket Price?

VXRT's last pre-market stock price is 0.6000 USD. The pre-market share volume is 10.0000, and the stock has decreased by 0.0400, or 7.1400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.